AQR Capital Management LLC Raises Stake in Teleflex Incorporated $TFX

AQR Capital Management LLC lifted its position in Teleflex Incorporated (NYSE:TFX - Free Report) by 7.4% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 292,523 shares of the medical technology company's stock after purchasing an additional 20,225 shares during the period. AQR Capital Management LLC owned about 0.66% of Teleflex worth $39,924,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors also recently modified their holdings of the company. MassMutual Private Wealth & Trust FSB lifted its position in shares of Teleflex by 103.1% in the first quarter. MassMutual Private Wealth & Trust FSB now owns 197 shares of the medical technology company's stock valued at $27,000 after acquiring an additional 100 shares in the last quarter. Banque Cantonale Vaudoise bought a new stake in Teleflex during the 1st quarter valued at approximately $27,000. Costello Asset Management INC bought a new stake in Teleflex during the 1st quarter valued at approximately $28,000. Brooklyn Investment Group lifted its holdings in Teleflex by 258.6% in the 1st quarter. Brooklyn Investment Group now owns 208 shares of the medical technology company's stock worth $29,000 after purchasing an additional 150 shares in the last quarter. Finally, Whipplewood Advisors LLC boosted its stake in Teleflex by 7,700.0% in the 1st quarter. Whipplewood Advisors LLC now owns 234 shares of the medical technology company's stock worth $32,000 after purchasing an additional 231 shares during the period. Hedge funds and other institutional investors own 95.62% of the company's stock.

Insider Transactions at Teleflex

In other news, Director Jaewon Ryu purchased 1,500 shares of the company's stock in a transaction that occurred on Tuesday, August 5th. The stock was purchased at an average cost of $115.00 per share, with a total value of $172,500.00. Following the purchase, the director owned 3,727 shares in the company, valued at approximately $428,605. This trade represents a 67.36% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Stuart A. Randle acquired 1,000 shares of Teleflex stock in a transaction that occurred on Tuesday, August 5th. The stock was purchased at an average cost of $115.86 per share, for a total transaction of $115,860.00. Following the completion of the transaction, the director directly owned 7,547 shares in the company, valued at $874,395.42. This trade represents a 15.27% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last ninety days, insiders have purchased 5,500 shares of company stock worth $633,590. 1.40% of the stock is currently owned by insiders.

Teleflex Trading Up 0.1%

TFX stock traded up $0.07 during midday trading on Wednesday, reaching $130.30. 858,756 shares of the company traded hands, compared to its average volume of 778,779. The firm has a market capitalization of $5.76 billion, a price-to-earnings ratio of 30.66, a P/E/G ratio of 1.82 and a beta of 1.08. Teleflex Incorporated has a 52-week low of $108.90 and a 52-week high of $249.90. The business has a 50 day moving average of $120.33 and a 200-day moving average of $127.05. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.44 and a current ratio of 2.41.

Teleflex (NYSE:TFX - Get Free Report) last announced its earnings results on Thursday, July 31st. The medical technology company reported $3.73 EPS for the quarter, topping analysts' consensus estimates of $3.36 by $0.37. Teleflex had a return on equity of 15.08% and a net margin of 6.31%.The firm had revenue of $780.90 million during the quarter, compared to analysts' expectations of $771.53 million. During the same quarter in the previous year, the business earned $3.42 EPS. The company's quarterly revenue was up 4.2% on a year-over-year basis. Teleflex has set its FY 2025 guidance at 13.900-14.300 EPS. As a group, sell-side analysts expect that Teleflex Incorporated will post 13.98 earnings per share for the current fiscal year.

Teleflex Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, September 15th. Stockholders of record on Friday, August 15th will be paid a $0.34 dividend. The ex-dividend date of this dividend is Friday, August 15th. This represents a $1.36 annualized dividend and a dividend yield of 1.0%. Teleflex's dividend payout ratio is currently 32.00%.

Analysts Set New Price Targets

A number of brokerages recently weighed in on TFX. Wall Street Zen upgraded shares of Teleflex from a "buy" rating to a "strong-buy" rating in a research report on Sunday. Wells Fargo & Company decreased their price target on shares of Teleflex from $137.00 to $131.00 and set an "equal weight" rating on the stock in a research note on Friday, August 1st. Royal Bank Of Canada lifted their target price on Teleflex from $130.00 to $135.00 and gave the stock a "sector perform" rating in a report on Friday, August 1st. Finally, Mizuho boosted their target price on Teleflex from $130.00 to $135.00 and gave the stock a "neutral" rating in a research report on Friday, August 1st. One research analyst has rated the stock with a Buy rating, eight have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and an average target price of $141.57.

About Teleflex

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.